- Home
- UONEK vs CYTH Comparison
UONEK vs CYTH Comparison
Compare UONEK & CYTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UONEK
- CYTH
- Stock Information
- Founded
- UONEK 1980
- CYTH 1990
- Country
- UONEK United States
- CYTH United States
- Employees
- UONEK N/A
- CYTH N/A
- Industry
- UONEK Broadcasting
- CYTH Biotechnology: Pharmaceutical Preparations
- Sector
- UONEK Consumer Discretionary
- CYTH Health Care
- Exchange
- UONEK Nasdaq
- CYTH Nasdaq
- Market Cap
- UONEK 38.3M
- CYTH 31.9M
- IPO Year
- UONEK N/A
- CYTH N/A
- Fundamental
- Price
- UONEK $0.79
- CYTH $0.91
- Analyst Decision
- UONEK
- CYTH Buy
- Analyst Count
- UONEK 0
- CYTH 3
- Target Price
- UONEK N/A
- CYTH $0.95
- AVG Volume (30 Days)
- UONEK 27.9K
- CYTH 4.5M
- Earning Date
- UONEK 11-12-2024
- CYTH 03-17-2025
- Dividend Yield
- UONEK N/A
- CYTH N/A
- EPS Growth
- UONEK N/A
- CYTH N/A
- EPS
- UONEK N/A
- CYTH N/A
- Revenue
- UONEK $452,891,000.00
- CYTH $870,725.00
- Revenue This Year
- UONEK N/A
- CYTH N/A
- Revenue Next Year
- UONEK N/A
- CYTH $24.49
- P/E Ratio
- UONEK N/A
- CYTH N/A
- Revenue Growth
- UONEK N/A
- CYTH N/A
- 52 Week Low
- UONEK $0.72
- CYTH $0.55
- 52 Week High
- UONEK $3.14
- CYTH $1.79
- Technical
- Relative Strength Index (RSI)
- UONEK 41.71
- CYTH 53.59
- Support Level
- UONEK $0.72
- CYTH $0.85
- Resistance Level
- UONEK $0.83
- CYTH $1.45
- Average True Range (ATR)
- UONEK 0.06
- CYTH 0.13
- MACD
- UONEK 0.01
- CYTH -0.00
- Stochastic Oscillator
- UONEK 36.11
- CYTH 22.83
About UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About CYTH Cyclo Therapeutics Inc.
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.